Natera, Inc. (NASDAQ:NTRA) Insider Sells $471,210.00 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $157.07, for a total transaction of $471,210.00. Following the sale, the insider now directly owns 133,205 shares in the company, valued at approximately $20,922,509.35. The trade was a 2.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Thursday, May 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $150.12, for a total transaction of $450,360.00.
• On Monday, April 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The shares were sold at an average price of $152.18, for a total transaction of $335,709.08.
• On Tuesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $140.48, for a total transaction of $421,440.00.
• On Monday, March 17th, Solomon Moshkevich sold 1,026 shares of Natera stock. The stock was sold at an average price of $146.04, for a total transaction of $149,837.04.

Natera Trading Down 1.1%

NTRA traded down $1.75 on Friday, hitting $163.76. The company had a trading volume of 1,016,903 shares, compared to its average volume of 1,409,610. The company's fifty day moving average price is $151.77 and its 200 day moving average price is $158.53. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The firm has a market cap of $22.36 billion, a P/E ratio of -93.05 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same period last year, the company earned ($0.56) earnings per share. The company's revenue for the quarter was up 36.5% on a year-over-year basis. As a group, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Natera by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock valued at $1,752,611,000 after purchasing an additional 77,357 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock worth $1,490,144,000 after acquiring an additional 3,795,315 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after purchasing an additional 660,538 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Natera by 15.7% in the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after acquiring an additional 439,778 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Natera by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after purchasing an additional 142,201 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. UBS Group boosted their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Royal Bank of Canada initiated coverage on shares of Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. Finally, Robert W. Baird lifted their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average price target of $184.63.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.